Hepatitis B Reactivation in a US Cohort of People With Human Immunodeficiency Virus and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity

Rachel Denyer; J. Tate; Debra Benator; J. K. Lim; Amy Weintrob

doi:10.1093/cid/ciag001

February 24, 2026Clinical Infectious DiseasesOpen Access

Hepatitis B Reactivation in a US Cohort of People With Human Immunodeficiency Virus and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the risk of hepatitis B virus reactivation in individuals with HIV and anti-HBV core antibody after changing antiretroviral therapy.
Analyzed a US cohort of individuals with HIV and anti-HBc antibody
Monitored HBV status after switching from HBV-active to non-HBV-active therapy
Assessed prior HBsAg status
Overall HBV reactivation risk was found to be low
No participants had prior HBsAg positivity
Findings aid in discussions between providers and patients about treatment options

Implication

Study finds low risk of HBV reactivation in HIV patients after switching to non-HBV-active ARVs, suggesting safety in treatment adjustment.

Abstract

Overall risk of HBV reactivation appears low after switch from HBV-active to non-HBV-active ARV among anti-HBc+ PWH with no prior HBsAg+. Our results inform provider-patient discussion about HBV reactivation risk when considering ARV switching.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Denyer et al. (2026) studied this question.

synapsesocial.com/papers/69be34886e48c4981c672ab3 https://doi.org/10.1093/cid/ciag001

View Full Paper

Ask AI

Bookmark

Share

Hepatitis B Reactivation in a US Cohort of People With Human Immunodeficiency Virus and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity

Key Points

Implication

Abstract

Discussion

Cite This Study

Hepatitis B Reactivation in a US Cohort of People With Human Immunodeficiency Virus and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading